Androgen receptor on the move: boarding the microtubule expressway to the nucleus - Wikidata - wikimedia - TriplyDB

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

http://www.wikidata.org/entity/Q26862560

about

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630 A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions Prognostic Significance and Functional Role of CEP57 in Prostate Cancer Androgen receptor splice variants determine taxane sensitivity in prostate cancer.The link between androgen receptor splice variants and castration-resistant prostate cancer.Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Mechanical aspects of microtubule bundling in taxane-treated circulating tumor cells Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer.Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer dCTP pyrophosphohydrase exhibits nucleic accumulation in multiple carcinomas.2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit Targeting microtubules by natural agents for cancer therapy.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Interphase microtubules: chief casualties in the war on cancer?Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Metastatic castration-resistant prostate cancer: time for innovation.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-κB and HSP90 in castration resistant prostate cancer.Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS).Mechanisms of Therapeutic Resistance in Prostate Cancer.Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.Clinical Development of Anti-mitotic Drugs in Cancer.Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT.Taxol®: The First Microtubule Stabilizing Agent.Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.The evolution of chemotherapy for the treatment of prostate cancer.Mechanisms of inhibition of endothelial cell migration by taxanes.Interactome Analysis of Microtubule-targeting Agents Reveals Cytotoxicity Bases in Normal Cells.

P2860

Q26858922-E6E5F4F7-3515-48BA-80E7-6E7E6D8FBC00 Q28540120-CE805CE9-00CD-4464-9670-3B2BC67537A0 Q28550159-FDC4C5CD-624D-416E-820F-DBDB5560B356 Q30361019-58EBECB5-25F1-4184-B98F-0D10B370E43A Q30577613-42E3E774-C4AE-4BA2-8CE8-6378E34AB315 Q30618562-06930538-4552-46AA-A08B-FDB40146E1AE Q33775726-5DD3213A-0C87-48CA-8299-CF9476AED876 Q33789192-25534EE0-A9E2-4590-A0B3-2C6A1D913BCC Q33946666-CCB8637F-26AE-41DF-B2DE-AD44DF1C646E Q34108738-66D35694-0700-462A-B318-84D994236F5C Q34144105-CB13BFF2-6018-4510-9B41-365826970107 Q34655256-8CCD97F4-A393-481E-9434-579F2B980473 Q35048550-12000FA3-F10E-498D-B6DF-291C7A219BBE Q35062586-4A7C8A36-CDAF-4E48-ABF4-DB68C0B1CAD5 Q35721526-A56975BD-E14D-4920-87CF-F1B43B0598A6 Q35956276-44E84C6F-854B-4416-AFD5-2968127297ED Q36410270-B84BEC1B-5081-446D-B5AC-22640C2644C9 Q36586089-EE0816B5-8904-4CCD-B207-845568532ED6 Q37224136-C9702AC8-0809-4D02-8018-BA18E1B10BE1 Q37323043-3B915368-DB1E-4C3B-BCD2-542242E06381 Q37620953-2B698B12-BC01-4028-A709-A03074BF6D81 Q37623838-0608E793-4FFB-42EE-A756-CBC76B39B34B Q38099046-557EF21D-AEC2-4A89-BD12-00543B37FEA0 Q38160670-CA43B4DD-E6DD-41BE-AE02-45DCC95C41A8 Q38183819-4ED04DAD-7CC3-4BB3-83AF-418CAC456B26 Q38312041-ECADC48F-1385-406C-9C18-CAA67425F27B Q38374417-637D567B-B174-4CC2-B341-3A4E3587FD4F Q38402398-A46AC013-D01A-4392-9214-F03D6A6E00FB Q38607675-5B289DB6-A6F4-447B-B033-4AF1121933B2 Q38744269-F070C542-5940-4DC5-B236-D6CC95D6B192 Q38754316-99E6EEF3-3946-4222-B532-97288C36830D Q38872725-F999ECDA-1EA7-4B39-8D72-A4FCE4387343 Q39363642-811AAF93-88A6-4FA7-BE2A-793348730A98 Q40262420-C7EA8E6E-312C-4755-BE1C-E4E939FB5682 Q41167484-B7830EED-FCED-41DB-BE0E-78AAA2870CCD Q41573963-43493ED6-2ECA-4F51-87D1-71C618C6851C Q42112858-4FDBE3AB-2875-4196-9C30-A6A3CB99A893 Q45943517-D494E8A5-BF0E-4505-86FF-D810A27DB73A Q46042101-8054C26D-1EE5-4274-8270-C6AE19372F7F Q47288270-2125C042-0355-40E1-B827-34B0094324E2

P2860

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

http://www.wikidata.org/entity/Q26862560

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@ast

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@en

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@nl

type

label

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@ast

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@en

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@nl

prefLabel

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@ast

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@en

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@nl

P1433

Q26862560-DF895A34-A2DE-47FD-808E-82A9755075CA

P1476

Q26862560-E44CE7C2-260C-4F98-8D4B-9772F882045A

P2093

Q26862560-1A640D9B-A17C-4530-84F7-7593D37BBD13

Q26862560-8C5796A8-0B46-4E44-8F40-7E5A8BB8F78B

Q26862560-B436A79D-183C-47FB-B5A5-5747283DDB2F

P2860

Q26862560-0E3F9964-4AC4-4354-99EC-45AF2571B70A

Q26862560-1157F34C-9DC9-448A-B177-9CE5E8D49E75

Q26862560-1248D8AD-409D-4445-ADA9-3836CCEC3F2E

Q26862560-16851BFC-4D35-4D6F-A104-4FC3BF18CE7F

Q26862560-2666C97C-FD4E-413D-BC30-29ECB749A46A

Q26862560-27F4BE91-789C-4A6A-8EEA-0E1A0963D698

Q26862560-2E288F6A-238E-4C0B-93ED-CB6C087EF100

Q26862560-2E98D355-7338-4F3F-B65D-98BB87C57AFB

Q26862560-2EC2642C-653D-4E5A-AC46-6411914E289E

Q26862560-303B6E1A-E2C2-4BA0-B82A-376DAB4BBA18

P304

Q26862560-2FC4358B-8105-415C-8E1A-BBEB47A7CC31

P31

Q26862560-33E3DA01-40DD-46B4-B0A3-42CD2D6DCA05

P3181

Q26862560-54AF5C43-3980-45CF-91CF-F0F853A7647C

P356

Q26862560-A8AF9BC8-D510-46D0-9976-1C9AEE48BC52

P407

Q26862560-8207E451-014C-4D64-8EF2-7987D07DC0AD

P433

Q26862560-31A1BF8A-A2DA-4831-9059-2096A84FC3D1

P478

Q26862560-1C9D740A-6534-46DB-8265-DEC19D4F08C8

P577

Q26862560-76A2209E-C3F6-4306-92C0-603B5DA3D4B8

P698

Q26862560-3F75B816-52D0-4ECC-BD60-6C6319EDB5BC

P921

Q26862560-D2FE7DDA-432D-4667-905A-B43ACD8C5779

P932

Q26862560-21F8F281-78F8-41C8-A9ED-6CC00880957B

P3181

P356

0008-5472.CAN-12-0783

P1433

Cancer Research

P1476

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

@en

P2093

D. M. Nanus

http://www.w3.org/2001/XMLSchema#string

M. Thadani-Mulero

http://www.w3.org/2001/XMLSchema#string

P. Giannakakou

http://www.w3.org/2001/XMLSchema#string

P2860

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale

Cancer statistics, 2012

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Molecular determinants of resistance to antiandrogen therapy

Microtubules as a target for anticancer drugs

The development of androgen-independent prostate cancer

P304

4611-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4649015

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-12-0783

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22987486

http://www.w3.org/2001/XMLSchema#string

P921

P932

3448065

http://www.w3.org/2001/XMLSchema#string